Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
SUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Endocrinologia e Metabologia
2022
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000200269 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2359-39972022000200269 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2359-399720220002002692022-05-10Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatmentAtaei-Nakhaei,SaeidehAryana,KamranMostafavi,Sayyed MostafaKosari,Hadis MohammadzadehEsmatinia,MohammadAghaee,AtenaSUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.66 n.2 20222022-04-01info:eu-repo/semantics/reporttext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000200269en10.20945/2359-3997000000451 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Ataei-Nakhaei,Saeideh Aryana,Kamran Mostafavi,Sayyed Mostafa Kosari,Hadis Mohammadzadeh Esmatinia,Mohammad Aghaee,Atena |
spellingShingle |
Ataei-Nakhaei,Saeideh Aryana,Kamran Mostafavi,Sayyed Mostafa Kosari,Hadis Mohammadzadeh Esmatinia,Mohammad Aghaee,Atena Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
author_facet |
Ataei-Nakhaei,Saeideh Aryana,Kamran Mostafavi,Sayyed Mostafa Kosari,Hadis Mohammadzadeh Esmatinia,Mohammad Aghaee,Atena |
author_sort |
Ataei-Nakhaei,Saeideh |
title |
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_short |
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_full |
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_fullStr |
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_full_unstemmed |
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
title_sort |
peptide receptor radionuclide therapy (prrt) in radioiodine-refractory thyroid cancer: a case report of significant response to lu177 dota-tate treatment |
description |
SUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response. |
publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
publishDate |
2022 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000200269 |
work_keys_str_mv |
AT ataeinakhaeisaeideh peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT aryanakamran peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT mostafavisayyedmostafa peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT kosarihadismohammadzadeh peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT esmatiniamohammad peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment AT aghaeeatena peptidereceptorradionuclidetherapyprrtinradioiodinerefractorythyroidcanceracasereportofsignificantresponsetolu177dotatatetreatment |
_version_ |
1756441496809111552 |